Non-Tuberculous Mycobacteria and <i<Aspergillus</i< Lung Co-Infection: Systematic Review
Non-tuberculous mycobacteria (NTM) and <i<Aspergillus</i< pulmonary co-infection occurs in patients with underlying lung disease and is rarely reported. We conducted a systematic search of NTM and <i<Aspergillus</i< pulmonary co-infection in PubMed, EMBASE, and Cochrane Library to identify cases published from 1977 to May 2022. We included 507 articles comprising 1538 cases (only 817 patients with partial relevant clinical data). Of these, 54.3% of patients were men, with a mean age of 57.7 years. Chronic obstructive pulmonary disease (21.1%), previous diagnosis of tuberculosis (18%), and asthma (11.1%) were the most common chronic lung diseases, and corticosteroids were used in 36.8% of patients. The most frequent symptoms were cough (68.2%), dyspnea (59.1%), and hemoptysis (34.1%). The most common radiological findings were bronchiectasis (52.3%) and cavitation (40.8%). NTM and <i<Aspergillus</i< were treated simultaneously in 47.3% of cases, whereas NTM-targeted therapy only was performed in 23.4% and <i<Aspergillus</i< only in 1.6%. The remaining 27.7% did not receive any treatment and were considered to be colonized. The global mortality rate was 43% (159/370). There was an increased prevalence of NTM and pulmonary aspergillosis among patients with underlying chronic lung diseases, which led to severe pulmonary affection with a poor global prognosis..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of Clinical Medicine - 11(2022), 19, p 5619 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marina Fayos [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.3390/jcm11195619 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ021329354 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ021329354 | ||
| 003 | DE-627 | ||
| 005 | 20240414184510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm11195619 |2 doi | |
| 035 | |a (DE-627)DOAJ021329354 | ||
| 035 | |a (DE-599)DOAJ80e586a552a84891aae89a2df50bc28e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Marina Fayos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Non-Tuberculous Mycobacteria and <i<Aspergillus</i< Lung Co-Infection: Systematic Review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Non-tuberculous mycobacteria (NTM) and <i<Aspergillus</i< pulmonary co-infection occurs in patients with underlying lung disease and is rarely reported. We conducted a systematic search of NTM and <i<Aspergillus</i< pulmonary co-infection in PubMed, EMBASE, and Cochrane Library to identify cases published from 1977 to May 2022. We included 507 articles comprising 1538 cases (only 817 patients with partial relevant clinical data). Of these, 54.3% of patients were men, with a mean age of 57.7 years. Chronic obstructive pulmonary disease (21.1%), previous diagnosis of tuberculosis (18%), and asthma (11.1%) were the most common chronic lung diseases, and corticosteroids were used in 36.8% of patients. The most frequent symptoms were cough (68.2%), dyspnea (59.1%), and hemoptysis (34.1%). The most common radiological findings were bronchiectasis (52.3%) and cavitation (40.8%). NTM and <i<Aspergillus</i< were treated simultaneously in 47.3% of cases, whereas NTM-targeted therapy only was performed in 23.4% and <i<Aspergillus</i< only in 1.6%. The remaining 27.7% did not receive any treatment and were considered to be colonized. The global mortality rate was 43% (159/370). There was an increased prevalence of NTM and pulmonary aspergillosis among patients with underlying chronic lung diseases, which led to severe pulmonary affection with a poor global prognosis. | ||
| 650 | 4 | |a non-tuberculous mycobacteria | |
| 650 | 4 | |a <i<Aspergillus</i< | |
| 650 | 4 | |a chronic lung disease | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Jose Tiago Silva |e verfasserin |4 aut | |
| 700 | 0 | |a Francisco López-Medrano |e verfasserin |4 aut | |
| 700 | 0 | |a José María Aguado |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Clinical Medicine |d MDPI AG, 2013 |g 11(2022), 19, p 5619 |w (DE-627)DOAJ000006793 |x 20770383 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:19, p 5619 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/jcm11195619 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/80e586a552a84891aae89a2df50bc28e |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2077-0383/11/19/5619 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2077-0383 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 19, p 5619 | ||